Related Experiment Video
Updated: Oct 25, 2025

Detection of Toxin Translocation into the Host Cytosol by Surface Plasmon Resonance
Published on: January 3, 2012
Human Peptides α-Defensin-1 and -5 Inhibit Pertussis Toxin
Carolin Kling1, Arto T Pulliainen2, Holger Barth1
1Institute of Pharmacology and Toxicology, Ulm University Medical Center, 89081 Ulm, Germany.
Insights
Human defensins, specifically alpha-defensin-1 and -5, inhibit pertussis toxin (PT) activity. These peptides show potential as novel therapeutics against whooping cough, a severe childhood disease.
Area of Science:
- Microbiology
- Immunology
- Toxicology
Background:
- Pertussis toxin (PT) from *Bordetella pertussis* is a key virulence factor causing whooping cough.
- PT disrupts cellular signaling by ADP-ribosylating inhibitory G-proteins (Gαi), affecting cAMP levels.
- Developing new PT inhibitors is crucial for effective whooping cough therapeutics.
Purpose of the Study:
- To investigate the inhibitory potential of human defensins against pertussis toxin.
- To identify novel therapeutic starting points for whooping cough treatment.
Main Methods:
- In vitro enzyme activity assays to assess PTS1 inhibition by defensins.
- Cell-based assays to measure Gαi ADP-ribosylation in the presence of PT and defensins.
- Cell-based interference in the Gαi-mediated signal transduction (iGIST) assay to evaluate effects on cAMP signaling.
Main Results:
- Alpha-defensin-1 and -5 significantly inhibited PTS1 enzyme activity in vitro.
- Alpha-defensins reduced Gαi ADP-ribosylation in PT-treated cells.
- Alpha-defensins mitigated PT-induced disruptions in cAMP signaling in living cells.
Conclusions:
- Human alpha-defensin-1 and -5 are effective inhibitors of pertussis toxin activity.
- These defensins represent promising candidates for developing new therapeutic strategies against whooping cough.
Abstract:
Bordetella pertussis causes the severe childhood disease whooping cough, by releasing several toxins, including pertussis toxin (PT) as a major virulence factor. PT is an AB5-type toxin, and consists of the enzymatic A-subunit PTS1 and five B-subunits, which facilitate binding to cells and transport of PTS1 into the cytosol. PTS1 ADP-ribosylates α-subunits of inhibitory G-proteins (Gαi) in the cytosol, which leads to disturbed cAMP signaling. Since PT is crucial for causing severe courses of disease, our aim is to identify new inhibitors against PT, to provide starting points for novel therapeutic approaches. Here, we investigated the effect of human antimicrobial peptides of the defensin family on PT. We demonstrated that PTS1 enzyme activity in vitro was inhibited by α-defensin-1 and -5, but not β-defensin-1. The amount of ADP-ribosylated Gαi was significantly reduced in PT-treated cells, in the presence of α-defensin-1 and -5. Moreover, both α-defensins decreased PT-mediated effects on cAMP signaling in the living cell-based interference in the Gαi-mediated signal transduction (iGIST) assay. Taken together, we identified the human peptides α-defensin-1 and -5 as inhibitors of PT activity, suggesting that these human peptides bear potential for developing novel therapeutic strategies against whooping cough.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
GPCRs Regulate Adenylyl Cylase Activity
Gene Regulation in Microbial Communities: Quorum Sensing

